|
|
Vaccine Detail
|
RAS Peptide Cancer Vaccine |
| Vaccine Information |
- Vaccine Name: RAS Peptide Cancer Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007035
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- KRAS
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Colon Cancer, Pancreatic Cancer and Lung Cancer (NCT00019006). A cancer vaccine containing a RAS oncogene-encoded peptide with potential antineoplastic activity. RAS peptide cancer vaccine may stimulate a RAS peptide-specific antitumoral T-cell cytotoxic immune response, resulting in an inhibition of tumor cell proliferation and tumor cell death (NCI04) (NCIT_C2438; Cafri et al., 2020).
|
| Host Response |
|
|
| References |
Cafri et al., 2020: Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD, Goff SL, McGowan CT, Seitter S, Shindorf ML, Parikh A, Chatani PD, Robbins PF, Rosenberg SA. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. The Journal of clinical investigation. 2020; 130(11); 5976-5988. [PubMed: 33016924].
NCIT_C2438: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2438]
NCT00019006: [https://clinicaltrials.gov/show/NCT00019006/]
|
|
